Jiabing Xu

Featured in: Favicon

bpspubs.onlinelibrary.wiley.com

Articles

Post‐marketing safety concerns with nirmatrelvir: A disproportionality analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System - Zhuang - British Journal of Clinical Pharmacology - Wiley Online Library

May 12, 2023 | bpspubs.onlinelibrary.wiley.com | Wei Zhuang |Jiabing Xu |Ye E Wu |Jianhui Yang

Abstract Aims Nirmatrelvir is an antiviral drug with a novel mechanism of action, targeting the 3-CL protease, and is used in the treatment of COVID-19. However, the potential side effects have not yet been fully studied. The aim of this study was to identify potential safety signals of nirmatrelvir by analysing post-marketing safety data based on the largest publicly available worldwide pharmacovigilance database.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →